About Instylla
Instylla is a company based in United States founded in 2017. It operates as a HealthTech. Instylla has raised $85.51 million across 4 funding rounds from investors including Delos Capital, Excelestar Ventures and Ascension Ventures. The company has 26 employees as of December 31, 2020. Instylla offers products and services including Embrace Hydrogel Embolic System and Tembo Embolic System.
- Headquarter United States
- Employees 26 as on 31 Dec, 2020
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Instylla, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$85.51 M (USD)
in 4 rounds
-
Latest Funding Round
$21.73 M (USD), Series B
Jul 07, 2025
-
Investors
Delos Capital
& 7 more
-
Employee Count
26
as on Dec 31, 2020
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Instylla
Instylla offers a comprehensive portfolio of products and services, including Embrace Hydrogel Embolic System and Tembo Embolic System.
Used for embolization of hypervascular peripheral tumors.
Designed for embolization in interventional radiology applications.
People of Instylla
Unlock access to complete
Unlock access to complete
Funding Insights of Instylla
Instylla has successfully raised a total of $85.51M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $21.73 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Instylla
Instylla has secured backing from 8 investors, including venture fund investors. Prominent investors backing the company include Delos Capital, Excelestar Ventures and Ascension Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Delos Capital is engaged in private equity and financial advisory services.
|
Locked | Locked | Locked | |
|
Late stage tech-focused VC firm funding companies in the US
|
Locked | Locked | Locked | |
|
Strategic investments in healthcare technologies and data innovations.
|
Locked | Locked | Locked |
Investor details for Instylla
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Instylla
Investment portfolio details for Instylla
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Instylla
Detailed financials for Instylla
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Instylla Comparisons
Peer comparison for Instylla
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Instylla
Detailed competitors of Instylla
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Instylla
Complete news archive for Instylla
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Instylla
Instylla was founded in 2017.
Instylla is headquartered in United States.
Instylla is a funded company, having raised a total of $85.51M across 4 funding rounds to date.
As of Dec 31, 2020, the latest employee count at Instylla is 26.
Instylla is focused on the development of next-generation liquid embolics for interventional radiology. Applications are primarily targeted at interventional oncology and peripheral hemostasis. Solutions like Embrace Hydrogel Embolic System are designed for embolization of hypervascular tumors in peripheral arteries. The company aims to advance medical procedures through innovative embolic systems.
Instylla offers Embrace Hydrogel Embolic System and Tembo Embolic System.
Instylla has 8 investors. Key investors include Delos Capital, Excelestar Ventures, Ascension Ventures, CHV, and AMED Ventures.